Real-World Assessment of Clinical Outcomes in Metastatic NSCLC Patients With MET Exon 14 Skipping Mutation and Brain Metastases Treated With Capmatinib

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

October 1, 2021

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions

Metastatic Non-Small Cell Lung Cancer

Interventions

DRUG

Capmatinib

Patients receiving Capmatinib

Trial Locations (1)

18 Novartis Investigative Sites in the US, East Hanover